Atossa Therapeutics (ATOS) Total Current Liabilities (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Total Current Liabilities of $7.5 million for Q1 2026, up 37.46% year-over-year from $5.4 million in Q1 2025, and down 9.67% quarter-over-quarter from $8.3 million in Q4 2025.
Atossa Therapeutics (ATOS) Total Current Liabilities (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Total Current Liabilities for 16 consecutive years, with $7.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 37.46% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $7.5 million (up 37.46% YoY), while the FY2025 annual figure was $8.3 million, up 66.2% from the prior year.
- Total Current Liabilities fell to $7.5 million in Q1 2026 per ATOS's latest filing, from $8.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $8.3 million in Q4 2025 and bottomed at $2.3 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $5.2 million across 5 years, with a median of $5.3 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 111.12% — and 2023, when it decreased 8.28%.
- Atossa Therapeutics' Total Current Liabilities stood at $5.6 million in 2022, then fell by 5.96% to $5.2 million in 2023, then slipped by 5.14% to $5.0 million in 2024, then surged by 66.2% to $8.3 million in 2025, then retreated by 9.67% to $7.5 million in 2026.
- Business Quant data shows ATOS's Total Current Liabilities at $7.5 million in Q1 2026, $8.3 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | 5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.45 Mn |
| Mar 31, 2026 | 7.46 Mn |
| Dec 31, 2025 | 8.26 Mn |
| Sep 30, 2025 | 8.23 Mn |
| Jun 30, 2025 | 6.82 Mn |
| Mar 31, 2025 | 5.43 Mn |
| Dec 31, 2024 | 4.97 Mn |
| Sep 30, 2024 | 5.80 Mn |
| Jun 30, 2024 | 5.70 Mn |
| Mar 31, 2024 | 5.33 Mn |
| Dec 31, 2023 | 5.24 Mn |
| Sep 30, 2023 | 3.44 Mn |
| Jun 30, 2023 | 3.48 Mn |
| Mar 31, 2023 | 2.94 Mn |
| Dec 31, 2022 | 5.57 Mn |
| Sep 30, 2022 | 2.87 Mn |
| Jun 30, 2022 | 3.79 Mn |
| Mar 31, 2022 | 2.32 Mn |
| Dec 31, 2021 | 3.13 Mn |
| Sep 30, 2021 | 1.68 Mn |